<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A10B&quot;,&quot;href&quot;:&quot;atc/A10B.md&quot;},{&quot;label&quot;:&quot;gliclazide&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Gliclazide_Frey2003_intersubject_variability&quot;,&quot;label&quot;:&quot;Frey_2003_intersubject_variability&quot;,&quot;href&quot;:&quot;drugs/drug_gliclazide/Gliclazide_Frey2003_intersubject_variability.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Gliclazide_Frey2003_parameters&quot;,&quot;label&quot;:&quot;Frey_2003_parameters&quot;,&quot;href&quot;:&quot;drugs/drug_gliclazide/Gliclazide_Frey2003_parameters.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Gliclazide_Frey2003_residual_variability&quot;,&quot;label&quot;:&quot;Frey_2003_residual_variability&quot;,&quot;href&quot;:&quot;drugs/drug_gliclazide/Gliclazide_Frey2003_residual_variability.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false}]"></div>

# gliclazide

- **generic name:** gliclazide
- **ATC codes:** `A10BB09`
- **DrugBank:** [DB01120](https://go.drugbank.com/drugs/DB01120) · **PubChem:** [CID 3475](https://pubchem.ncbi.nlm.nih.gov/compound/3475)
- **molar mass:** 323.41 g/mol (C15H21N3O3S) — DrugBank
- **groups:** approved, investigational

## About

**Description.** Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group.[A39546] On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life.[T238, T360] Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating &beta; cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic &beta; cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).

**Indication.** For the treatment of NIDDM in conjunction with diet and exercise.

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 21:42 | 5:47 | 3/0/0 | 0/0/1 | 0/0/0 | 124,925/10,550 | ollama / qwen3.8:27b-mtp-q8_0 | 10 | 1/0 | 2/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span><br><sub>blocking: T6_deviations</sub><br><sub>route_to: `engineer`</sub> | [Frey_2003_intersubject_variability](drugs/drug_gliclazide/Gliclazide_Frey2003_intersubject_variability.md) | ▶ model + simulator | 1-compartment, oral | 3 | Frey N et al., Population PKPD modelling of the long-t…, British journal of clinical… (2003) | [10.1046/j.1365-2125.2003.01751.x](https://doi.org/10.1046/j.1365-2125.2003.01751.x) |
| <span class="pk-badge pk-badge--orange">needs review</span><br><sub>blocking: T6_deviations</sub><br><sub>route_to: `engineer`</sub> | [Frey_2003_parameters](drugs/drug_gliclazide/Gliclazide_Frey2003_parameters.md) | ▶ model + simulator | 1-compartment, oral | 4 | Frey N et al., Population PKPD modelling of the long-t…, British journal of clinical… (2003) | [10.1046/j.1365-2125.2003.01751.x](https://doi.org/10.1046/j.1365-2125.2003.01751.x) |
| <span class="pk-badge pk-badge--orange">needs review</span><br><sub>blocking: T6_deviations</sub><br><sub>route_to: `engineer`</sub> | [Frey_2003_residual_variability](drugs/drug_gliclazide/Gliclazide_Frey2003_residual_variability.md) | ▶ model + simulator | 1-compartment, oral | 3 | Frey N et al., Population PKPD modelling of the long-t…, British journal of clinical… (2003) | [10.1046/j.1365-2125.2003.01751.x](https://doi.org/10.1046/j.1365-2125.2003.01751.x) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> | [Frey_2003_fasting_plasma_glucose](drugs/drug_gliclazide/pd_Frey_2003_fasting_plasma_glucose.md) | name ← gliclazide · direct Emax (saturable) effect | — | Frey N et al., Population PKPD modelling of the long-t…, British journal of clinical… (2003) | [10.1046/j.1365-2125.2003.01751.x](https://doi.org/10.1046/j.1365-2125.2003.01751.x) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=gliclazide) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| distribution | blood | `ALB` unknown | DrugBank actor |
| metabolism | kidney | <sub>“…1% of the orally administered dose appears unchanged in the urine. Metabolites include oxi…”</sub> | prose |
| metabolism | liver | `CYP2C19` substrate, `CYP2C9` substrate | DrugBank actor |
| excretion | bile duct | <sub>“…liminated primarily by the kidneys (60-70%) and also in the feces (10-20%).…”</sub> | prose |
| excretion | kidney | <sub>“…Metabolites and conjugates are eliminated primarily by the kidneys (60-70%) and also in th…”</sub> | prose |

<sub>Actors without a tissue in the table: ABCC8 (binder), VEGFA (other/unknown).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 12 matched, 12 returned
- **screened:** 7  ·  **relevant:** 7
- **records:** 3  ·  extracted 0  ·  needs_review 3  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_8 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Adiwidjaja_2021.pdf` | Adiwidjaja J et al., Effect of Nigella sativa oil on pharmac…, Biopharmaceutics & drug dis… (2021) | popPK | 10 | [10.1002/bdd.2300](https://doi.org/10.1002/bdd.2300) | [34327715](https://pubmed.ncbi.nlm.nih.gov/34327715) | The paper directly reports quantitative population pharmacokinetic parameters for gliclazide in rats, with all key model estimates clearly tabulated in the provided text. |
| `Brendel_2006.pdf` | Brendel K et al., Metrics for external model evaluation w…, Pharmaceutical research (2006) | popPK | 10 | [10.1007/s11095-006-9067-5](https://doi.org/10.1007/s11095-006-9067-5) | [16906454](https://pubmed.ncbi.nlm.nih.gov/16906454) | The population PK parameters for gliclazide are explicitly reported with numeric estimates and standard errors in Table I within the provided full text. |
| `Brendel_2010.pdf` | Brendel K et al., Evaluation of different tests based on…, Journal of pharmacokinetics… (2010) | popPK | 10 | [10.1007/s10928-009-9143-7](https://doi.org/10.1007/s10928-009-9143-7) | [20033477](https://pubmed.ncbi.nlm.nih.gov/20033477) | The paper reports a population pharmacokinetic model for gliclazide with all quantitative parameter estimates clearly provided in Table 1 within the main text. |
| `Shaik_2018_2.pdf` | Shaik M et al., Population pharmacokinetics of gliclazi…, Biopharmaceutics & drug dis… (2018) | popPK | 10 | [10.1002/bdd.2132](https://doi.org/10.1002/bdd.2132) | [29679474](https://pubmed.ncbi.nlm.nih.gov/29679474) | The study reports quantitative population PK parameters (CL, V, ka) for gliclazide in rabbits, with all numeric values explicitly present in the text. |
| `Cho_2009.pdf` | Cho HY et al., Pharmacokinetics and bioequivalence eva…, International journal of cl… (2009) | popPK | 8 | [10.5414/cpp47770](https://doi.org/10.5414/cpp47770) | [19954716](https://pubmed.ncbi.nlm.nih.gov/19954716) | The study reports quantitative pharmacokinetic parameters for gliclazide, and all numeric values are directly available in the provided main tables. |
| `Rojanasthien_2012.pdf` | Rojanasthien N et al., Bioequivalence study of modified-releas…, ISRN pharmacology (2012) | popPK | 8 | [10.5402/2012/375134](https://doi.org/10.5402/2012/375134) | [23029622](https://pubmed.ncbi.nlm.nih.gov/23029622) | The study reports original pharmacokinetic parameters for gliclazide with all numeric values clearly available in the provided tables and text. |
| `Samad_2011.pdf` | Samad A et al., Pharmacokinetic-pharmacodynamic equival…, International journal of cl… (2011) | popPK | 8 | [10.5414/cp201504](https://doi.org/10.5414/cp201504) | [21726495](https://pubmed.ncbi.nlm.nih.gov/21726495) | The study reports PK parameters for gliclazide, but the specific numeric values for clearance, volume, or half-life are not present in the provided text, only ranges and qualitative statements of bioequivalence. |
| `Stetinová_2007.pdf` | Stetinová V et al., Gliclazide: pharmacokinetic-pharmacodyn…, Biopharmaceutics & drug dis… (2007) | popPK | 8 | [10.1002/bdd.550](https://doi.org/10.1002/bdd.550) | [17415747](https://pubmed.ncbi.nlm.nih.gov/17415747) | The paper is a PK/PD study of gliclazide in rats, but the provided evidence contains only qualitative descriptions and glucose response percentages, lacking specific numeric PK parameters like clearance or volume. |

<sub>queue written 2026-09-15T21:37:15.994815+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Lim_2004 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of ion channels in Xenopus oocytes and does not report pharmacokinetic parameters for gliclazide. |
| PD | Lim_2004 | not_relevant | 0 | 0 | The paper reports IC50 values for taurine (not gliclazide) and states that gliclazide binding was not modified by taurine, but it does not provide a concentration-effect curve or numeric PD parameters for gliclazide itself. |
| popPK | Mim_2023 | relevant | 9 | 0 | The abstract describes a population PK model development for gliclazide but contains no numeric parameter estimates, which are likely in the full text or supplementary materials not provided. |
| popPK | Rojanasthien_2003 | relevant | 4 | 5 | The study reports non-compartmental PK parameters (t1/2, Tmax) for gliclazide, but lacks compartmental model parameters (CL, V, Q) required for population PK extraction. |
| popPK | Samad_2011 | relevant | 8 | 2 | The study reports PK parameters for gliclazide, but the specific numeric values for clearance, volume, or half-life are not present in the provided text, only ranges and qualitative statements of bioequivalence. |
| PD | Samad_2011 | not_relevant | 4 | 2 | The paper reports PK/PD bioequivalence using surrogate PD parameters (Cmin_glu, Tmax_glu) but does not provide a concentration-effect model or numeric PD parameters (e.g., Emax, EC50) in the text. |
| popPK | Stetinová_2007 | relevant | 8 | 0 | The paper is a PK/PD study of gliclazide in rats, but the provided evidence contains only qualitative descriptions and glucose response percentages, lacking specific numeric PK parameters like clearance or volume. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-15 21:37 UTC</sub>
